Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: May 22, 2006
Last updated: April 11, 2013
Last verified: November 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2004
  Primary Completion Date: April 2004 (Final data collection date for primary outcome measure)
Hollander P, Weston WM, Huang C, Chou H, and Porter LE. Low dose rosiglitazone significantly improves glycemic control without increasing adverse events in patients with T2DM not well controlled on insulin. Diabetes 2005;54(suppl 1):A3-4. Abstract 12-OR.